St. Jude To Demo OCT At TCT 2010
Medical devices giant St. Jude Medical Inc. (STJ) will showcase its recently launched Optical Coherence Tomography (OCT) technology (a next-generation imaging technology) platform at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) scientific meet in Washington, DC. TCT is the world’s largest educational meeting focused on interventional cardiovascular medicine.
OCT is an optical signal acquisition and processing technique that employs near-infrared light to generate high-resolution images that are 10 times better (in resolution) and 20 times faster (in image capture) than those produced by the competing intravascular ultrasound imaging systems (IVUS) marketed by incumbent players such as Volcano Corp (VOLC) and Boston Scientific
LightLab received the U.S. regulatory approval for its first OCT products, the C7-XR OCT intravascular imaging system and companion C7 Dragonfly imaging catheter, in May 2010. The C7-XR imaging system is an optical imaging technology that helps physicians diagnose and treat cardiovascular conditions. St. Jude will introduce the C7-XR system, its first OCT offering, at the TCT 2010.
With its LightLab acquisition, St. Jude has emerged as the first company to offer a comprehensive lesion assessment product portfolio that includes both OCT and its Fractional Flow Reserve (FFR) technology, an index that identifies and measures the severity of coronary artery narrowing.
Besides the new OCT system, St. Jude will also highlight its PressureWire FFR platform at the TCT 2010. Moreover, the company will host virtual reality simulation sessions on OCT-guided therapy and PressureWire for the physicians at the meeting.
OCT is an optical signal acquisition and processing technique that employs near-infrared light to generate high-resolution images that are 10 times better (in resolution) and 20 times faster (in image capture) than those produced by the competing intravascular ultrasound imaging systems (IVUS) marketed by incumbent players such as Volcano Corp (VOLC) and Boston Scientific
LightLab received the U.S. regulatory approval for its first OCT products, the C7-XR OCT intravascular imaging system and companion C7 Dragonfly imaging catheter, in May 2010. The C7-XR imaging system is an optical imaging technology that helps physicians diagnose and treat cardiovascular conditions. St. Jude will introduce the C7-XR system, its first OCT offering, at the TCT 2010.
With its LightLab acquisition, St. Jude has emerged as the first company to offer a comprehensive lesion assessment product portfolio that includes both OCT and its Fractional Flow Reserve (FFR) technology, an index that identifies and measures the severity of coronary artery narrowing.
Besides the new OCT system, St. Jude will also highlight its PressureWire FFR platform at the TCT 2010. Moreover, the company will host virtual reality simulation sessions on OCT-guided therapy and PressureWire for the physicians at the meeting.
The unique combination (OCT-FFR) provides cardiologists with comprehensive information to assess and determine the lesions that warrant coronary interventions, resulting in better treatment outcomes. St. Jude expects the OCT platform to offer an additional $20 million in revenues to its cardiovascular business during second-half 2010.
| Analysts' Targets | |
| Barclays Capital | $50 |
| Equal Weight | |
| Friday, March 25, 2011 | |
| Deutsche Bank Securities | $52 |
| Accumulate | |
| Monday, February 07, 2011 | |
| RBC Capital Markets | $44 |
| Sector Perform | |
| Wednesday, January 05, 2011 | |
| Longbow | $38 |
| Neutral | |
| Thursday, October 21, 2010 | |
No comments:
Post a Comment